Trial Purpose

Substudy 02A is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study.

The goal of substudy 02A is to evaluate the safety and efficacy of investigational treatment arms in participants with PD-1 refractory melanoma to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available.

Learn More on ClinicalTrials.gov

CLINICALTRIALS.GOV IDENTIFIER:

NCT04305041

When speaking to your doctor, please have the trial identifier number available.

About The Study

Trial Phase Icon

Phase 1

Tests the medicine or vaccine in a small group of 20 to 100 volunteers who are usually healthy, but not always. The trial often takes place in a hospital.

Phase 2

Tests the medicine or vaccine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy.

Trial start Icon

Dates

  • Actual study start date 26 June 2020
  • Estimated primary completion date 3 April 2030
  • Estimated study completion date 3 April 2030

Eligibility

Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.

Conditions Icon

Conditions

Melanoma

Age Range Icon

Age Range

18 - 120

Sex Icon

Sex

All

Trial locations

Locations provided may not reflect the most current site information. Please call the number provided in the location results to confirm.